Scarica l'app Stockscreener
2.46
2.50%
0.06
Dopo l'orario di chiusura:
2.36
-0.10
-4.07%
Precedente Chiudi:
$2.40
Aprire:
$2.35
Volume 24 ore:
1.56M
Relative Volume:
0.63
Capitalizzazione di mercato:
$371.53M
Reddito:
$7.25M
Utile/perdita netta:
$-17.41M
Rapporto P/E:
-9.3643
EPS:
-0.2627
Flusso di cassa netto:
$-38.33M
1 W Prestazione:
+6.96%
1M Prestazione:
+49.09%
6M Prestazione:
+42.20%
1 anno Prestazione:
+504.42%
Intervallo 1D:
$2.3101
$2.525
Intervallo di 1 settimana:
$2.3101
$2.72
Portata 52W:
$0.2425
$2.72
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.46 | 362.47M | 7.25M | -17.41M | -38.33M | -0.2627 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Iniziato | Roth Capital | Buy |
| 2025-11-17 | Iniziato | Leerink Partners | Outperform |
| 2025-10-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-08 | Ripresa | B. Riley Securities | Buy |
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Ovid Therapeutics (NASDAQ: OVID) chair exercises 47,333-share warrant at $1.40 - Stock Titan
Investors pour $60M into Ovid Therapeutics to advance seizure drugs - Crain's New York
Ovid Therapeutics secures $60M funding to advance epilepsy drug programs - MSN
Ovid Therapeutics' new epilepsy trial data ignites rally - MSN
If You Invested $1,000 in Ovid Therapeutics Inc (OVID) - Stock Titan
Here's why Ovid Therapeutics stock popped higher today - MSN
Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to Hold - MarketBeat
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma - MSN
Ovid Therapeutics Stock Surges on Positive Drug Trial Data and Financing Plans - StocksToTrade
Ovid Shares Surge with Positive Phase 1 Results and Strategic Moves - timothysykes.com
Wedbush Forecasts Strong Price Appreciation for Ovid Therapeutics (NASDAQ:OVID) Stock - MarketBeat
Ovid Therapeutics (OVID) Sees Price Target Raised by Wedbush | O - GuruFocus
Bond Watch: How does Ovid Therapeutics Inc score in quality rankingsMarket Performance Report & Daily Technical Forecast Reports - baoquankhu1.vn
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding - Seeking Alpha
Here's Why Ovid Therapeutics Stock Popped Higher Today - AOL.com
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com
Ovid Therapeutics Hits New 52-Week High of $2.50, Marking Major Milestone - Markets Mojo
Leerink reiterates Ovid Therapeutics stock rating on safety data By Investing.com - Investing.com South Africa
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally - Sahm
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results - Sahm
Leerink reiterates Ovid Therapeutics stock rating on safety data - Investing.com
Ovid Therapeutics advances OV329 epilepsy drug, secures $60M financing - MSN
Ovid’s KCC2 direct activator OV-4071 cleared for clinic - BioWorld MedTech
Ovid Therapeutics (OVID) Q4 earnings and revenues surpass estimates - MSN
Ovid Therapeutics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:OVID) 2026-03-19 - Seeking Alpha
Ovid Therapeutics Shares Surge After Positive Epilepsy Drug Trial Results - MSN
Ovid Therapeutics raises $60 million to expand drug development By Investing.com - Investing.com South Africa
Ovid Therapeutics raises $60M, expands epilepsy drug development By Investing.com - Investing.com South Africa
Ovid Therapeutics: Advancing Small Molecule Medicines for Epilepsy and Psychiatric Disorders – Pipeline, Strategy, and Company Overview - Minichart
Ovid Therapeutics (OVID) Q4 Profit Challenges Ongoing Loss Narrative - simplywall.st
Earnings Call Summary | Ovid Therapeutics(OVID.US) Q4 2025 Earnings Conference - 富途牛牛
Ovid Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Ovid Therapeutics Q4 Earnings Call Highlights - MarketBeat
Ovid Therapeutics 2025 10-K: $7.3M Revenue, $(17.41)M Net Loss - TradingView
OVID: 2025 saw higher revenue, reduced losses, and strong cash to support advancing CNS drug programs - TradingView
[10-K] Ovid Therapeutics Inc. Files Annual Report | OVID SEC FilingForm 10-K - Stock Titan
Ovid Therapeutics (OVID) Reports Strong Q4 Revenue and Expands C - GuruFocus
Ovid Therapeutics (OVID) Swings to $0.06 EPS in Q4 FY25 - AlphaStreet
Here's Why Ovid Therapeutics Stock Popped Higher Today - The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Ovid Therapeutics Expands OV329 Epilepsy Program, Launches Phase 1 OV4071 Trial, and Reports Strong 2025 Financial Results - Minichart
Ovid Therapeutics Faces Market Uncertainty Amid Recent Earnings Review - StocksToTrade
Earnings call transcript: Ovid Therapeutics Q4 2025 Surprises with Earnings Beat - Investing.com
OVID’s Latest Strategic Moves Propel Stock Price Surge - timothysykes.com
Ovid Therapeutics earnings beat by $0.17, revenue topped estimates - Investing.com Canada
Ovid Therapeutics Inc. announced that it expects to receive $59.99992 million in funding from a group of investors - marketscreener.com
Ovid Therapeutics (OVID) Q4 Results Exceed Expectations for Earnings and Revenue - Bitget
Ovid (OVID) Reports Strong Cash Position as of Year-End 2025 - GuruFocus
Ovid Raises $60 Million in PIPE at $2.01, Including Pre-Funded Warrants - TradingView
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.04%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):